Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
Nasopharyngeal Cancers
About this trial
This is an interventional treatment trial for Nasopharyngeal Cancers focused on measuring rhGM-CSF, Oral Mucositis, Primary Nasopharyngeal Cancers, Chemoradiotherapy
Eligibility Criteria
Inclusion Criteria:
- Grade II oral mucositis induced by chemoradiotherapy in patient with primary nasopharyngeal carcinoma.
- Receiving 68-72 Gray of radiation dose.
- Age between 18 and 65 years.
- KPS≥70.
- Patient who has given his/her written consent before any specific procedure of the protocol.
Exclusion Criteria:
- Severe uncontrolled infection.
- Pregnant or breast-feeding females.
- Allergy to this medicine.
- Diarrhea.
Sites / Locations
- Sun Yat-sen University Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm A
Arm B
Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily. Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.
Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily Radiotherapy: Intensity modulated radiation therapy(IMRT) Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.